Opinion|Videos|July 29, 2024
Decision-Making in CLL: The Role of Real-World Evidence
A discussion on therapeutic decision-making in CLL and the role of real-world evidence.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- How do you integrate real-world evidence into your clinical decision-making process for BTK inhibitors in CLL?
Advertisement
Related to this article
Even when physicians prescribe guideline-preferred therapies, step therapy and prior authorization can delay or restrict access to CLL therapies.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
NEI Director Highlights Pediatric Advances, AI’s Promise in Eye Care
3
GLP-1s Have Protective Benefit Against DME, Glaucoma Surgery
4
Keynote Address Tackles AI’s Role in Health Care, Eye Care
5